FDA approves second monoclonal antibody treatment for early Alzheimer’s disease
By
Kristen Fischer
Jul 02, 2024
The US Food and Drug Administration (FDA) approved a second monoclonal antibody treatment for for early Alzheimer’s on Tuesday. Eli Lilly’s Kisunla (donanemab), which has proven to slow the disease...
Clinical briefs for Thursday, May 16
By
Kristen Fischer
May 15, 2024
Study: Sleep apnea severity linked to verbal memory decline … Test ties mobility to cognitive function … Spotting osteosarcopenia in heart valve operation patients could predict post-surgical death...
Clinical briefs for Tuesday, Oct. 3
By
Kristen Fischer
Oct 03, 2023
WHO: Switch back to trivalent flu shots … Vascular cells needed to form long-term memories … Radiation could treat inoperable kidney tumors … “Expired” COVID-19 tests may still be OK, feds say...
Study questions fish oil claims, popularity
By
Kristen Fischer
Aug 24, 2023
One in every five adults aged more than 60 years takes fish oil supplements, despite many warnings that they have no benefit for heart health. A new study sheds light on what the product labels say that...
CMS must allow nursing homes to treat neuropsychiatric symptoms of Alzheimer’s
By
Sue Peschin
Chad Worz
Jan 09, 2024
As we start 2024 anew and recover from family-filled holidays, we may have been reminded that celebrations often serve double duty as an informal assessment of health and well-being — including neuropsychiatric...